View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 4, 2021

Covid-19 vaccines show efficacy in adolescents, paving path towards herd immunity

There are globally now more people vaccinated for COVID-19 than confirmed cases of COVID-19. With globally over 400 million people fully vaccinated and over 1.7 billion vaccine doses administered, herd immunity seems achievable.

By GlobalData Healthcare

There are globally now more people vaccinated for COVID-19 than confirmed cases of COVID-19. With globally over 400 million people fully vaccinated and over 1.7 billion vaccine doses administered, herd immunity seems achievable. However, unvaccinated proportions of the population remain, including adolescents ages 12–15 years. Getting this proportion of the population vaccinated will aid in approaching herd immunity as there are approximately 17 million adolescents in the US.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Two of the leading COVID-19 vaccines have shown efficacy in adolescents in recent clinical trials: Pfizer/BioNTech’s Comirnaty and Moderna’s mRNA-1273. A Phase III trial of the Pfizer/BioNTech COVID-19 vaccine in 2,260 adolescents ages 12–15 years demonstrated 100% efficacy, robust antibody response, and was well tolerated. Comirnaty is now recommended by the US Centers for Disease Control and Prevention (CDC) and authorized by the FDA for adolescents. Providers are now vaccinating adolescents, and more than 600,000 adolescents ages 12–15 years have been vaccinated in the second week of May. Canada has also previously authorized the vaccine for adolescents ages 12–15 years, and the European Medicines Agency (EMA) is reviewing an application to extend Comirnaty to include ages 12–15 years. The outcome of the EMA’s evaluation is expected in June.

Moderna’s mRNA-1273 vaccine has also recently reported that preliminary data from 3,235 adolescents ages 12–17 years showed that the vaccine had 96% efficacy. Moderna reported no serious safety concerns and is seeking emergency use authorization from the FDA for adolescents. Moderna also has supporting data for the efficacy of a variant-directed vaccine, opening up the possibility for future vaccine boosters to address variants of concern and update the current vaccine to adapt to changes in the SARS-CoV-2 virus.

While COVID-19 mostly causes mild to no symptoms in children, some can get severely ill, and recent data shows that children are making up an increasing share of new COVID-19 cases. SARS-CoV-2 is estimated to have infected more than 3.78 million children, although death caused by COVID-19 in children is rare. The vaccine will allow for a return to normalcy for this age group, help allow schools to safely reopen, and improve mental health by allowing adolescents to resume normal activities.

Pfizer expects to collect a staggering $26B in revenue from its COVID-19 vaccine Comirnaty in 2021. Meanwhile, Moderna is projecting $19.2B in COVID-19 sales this year, according to the company’s Q1 statement.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU